Oppenheimer Reiterates Outperform on DiaMedica Therapeutics, Maintains $6 Price Target
Benzinga Newsdesk 2 years ago
NewsPrice TargetReiterationAnalyst Ratings
Oppenheimer analyst Francois Brisebois reiterates DiaMedica Therapeutics (NASDAQ:DMAC) with a Outperform and maintains $6 price target.
Oppenheimer analyst Francois Brisebois reiterates DiaMedica Therapeutics (NASDAQ:DMAC) with a Outperform and maintains $6 price target.